Merck KGaA: UBS raises target price

(CercleFinance.com) - UBS confirms its Buy recommendation on the stock, raising its price target to E185 (from E178), which represents 14% upside potential.


"FY24 & FY25 EPS raised post strong 2Q and guidance upgrade. +ve Electronics & improving back drop in Life Sciences offset by lack of innovation in Healthcare" UBS says.

Merck has raised its targets for 2024 as well as for the Healthcare and Electronics business sectors. The Group expects net sales in the range of E20.7bn to E22.1bn and organic growth of +2% to +5% (previously: E20.6bn to E22.1bn; organic growth of +1% to +5%).

EBITDA should be E5.8bn to E6.4bn, with organic growth of +4% to +10% (previously: E5.7bn to E6.3bn; organic growth of +1% to +7%). EPS is now expected between E8.20 and E9.30 (previously: E8.05 to E9.10).


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.